[ad_1] RT @ThomasCiullaMD: Congrats to colleagues & partners with numerous #arvo2022 presentations on #suprachoroidal delivery, with the SCS Micr… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] RT @Healio_OSN: Two phase 3 studies showed that suprachoroidal triamcinolone acetonide injections led to significant improvement in visual… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
At #arvo2022, with colleagues who worked at Spark prior to #Luxturna launch, which involved novel functional vision #endpoints, complex #genetictesting paradigms, new administration procedures at treatment centers, & unique reimbursement pathways associated with #genetherapy https://t.co/MMo8oZeVD5
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] Congrats to colleagues & partners with numerous #arvo2022 presentations on #suprachoroidal delivery, with the SCS Microinjector. In addition to FDA-approved #Xipere, 6 clinical trials globally are assessing 4 different investigational therapies, using the SCS Microinjector.#eye https://t.co/TFshyatTTH [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] RT @eyetubenet: Join Drs. Sunil Srivastava, Dilraj Grewal, and Steven Yeh for this #CME Series: Harnessing the Suprachoroidal Space for the… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
RT @ThomasCiullaMD: Just published: https://t.co/pGZQQVEySc Disease progression pathways of wet AMD: opportunities for new target discovery…
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] Looking forward to ARVO 2022 meeting next week. Check out these excellent presentations providing insights on #suprachoroidal delivery of investigational agents, a corticosteroid, and a #genetherapy. #xipere #uveitis #AMD #diabeticretinopathy #retina #biotech #clinicalresearch https://t.co/havK3tYkqD [ad_2] Source by Thomas Ciulla, MD, MBA Return to main …
[ad_1] RT @ThomasCiullaMD: This webinar on #suprachoroidal delivery features an amazingly talented team: [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
Just published: This work supports the favorable targeting, compartmentalization and durability of the first FDA-approved #suprachoroidal therapy…#eyes #retina #xipere #uveitis https://t.co/LQ0o7aZkmS
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] RT @RetinaToday: How Will Suprachoroidal Injections Alter the Treatment Landscape? View more from @EvolveMedEd: https://t.co/NjPvvseOWE htt… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.